share_log

啓明醫療-B：截至二零二三年十二月三十一日止年度之年度業績公告

VENUS MEDTECH-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 28 10:15
Summary by Moomoo AI
杭州啓明醫療器械股份有限公司（「啓明醫療」）公布截至2023年12月31日止年度未經審核綜合業績。報告顯示，公司收入達491,373萬人民幣，較去年同期增長20.9%；毛利389,205萬人民幣，增長24.0%。儘管收入及毛利均有所增加，但公司年內虧損為746,178萬人民幣，較去年減少33.5%。母公司擁有人應佔虧損720,876萬人民幣，每股虧損為人民幣1.65元。公司研發成本為524,915萬人民幣，與去年相近。報告期內，公司未派發末期股息，並繼續在聯交所暫停買賣股份。
杭州啓明醫療器械股份有限公司（「啓明醫療」）公布截至2023年12月31日止年度未經審核綜合業績。報告顯示，公司收入達491,373萬人民幣，較去年同期增長20.9%；毛利389,205萬人民幣，增長24.0%。儘管收入及毛利均有所增加，但公司年內虧損為746,178萬人民幣，較去年減少33.5%。母公司擁有人應佔虧損720,876萬人民幣，每股虧損為人民幣1.65元。公司研發成本為524,915萬人民幣，與去年相近。報告期內，公司未派發末期股息，並繼續在聯交所暫停買賣股份。
Hangzhou Kaiming Medical Equipment Co., Ltd. (“Kai Ming Medical”) announces unaudited consolidated results for the year ended December 31, 2023. The report showed that the company's revenue reached RMB 491,373 million, an increase of 20.9% over the same period last year; gross profit of RMB 389,205 million, an increase of 24.0%. Despite the increase in revenue and gross profit, the company's loss for the year amounted to RMB 746,178 million, down 33.5% from last year. The owners of the parent company accounted for a loss of RMB720,876 million and a loss of RMB1.65 per share. The company's R&D cost is RMB 524,915 million, which is close to last year. During the reporting period, the company did not issue a final dividend and continued to suspend trading on the exchange.
Hangzhou Kaiming Medical Equipment Co., Ltd. (“Kai Ming Medical”) announces unaudited consolidated results for the year ended December 31, 2023. The report showed that the company's revenue reached RMB 491,373 million, an increase of 20.9% over the same period last year; gross profit of RMB 389,205 million, an increase of 24.0%. Despite the increase in revenue and gross profit, the company's loss for the year amounted to RMB 746,178 million, down 33.5% from last year. The owners of the parent company accounted for a loss of RMB720,876 million and a loss of RMB1.65 per share. The company's R&D cost is RMB 524,915 million, which is close to last year. During the reporting period, the company did not issue a final dividend and continued to suspend trading on the exchange.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more